Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease

Stephen Zano, Radhika Malik, Sylvia Szucs, Reuben Matalon, Ronald E. Viola

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Canavan disease is a fatal neurological disease without any effective treatments to slow the relentless progress of this disorder. Enzyme replacement therapy has been used effectively to treat a number of metabolic disorders, but the presence of the blood-brain-barrier presents an additional challenge in the treatment of neurological disorders. Studies have begun with the aim of establishing a treatment protocol that can effectively replace the defective enzyme in Canavan disease patients. The human enzyme, aspartoacylase, has been cloned, expressed and purified, and the surface lysyl groups modified through PEGylation. Fully active modified enzymes were administered to mice that are defective in this enzyme and that show many of the symptoms of Canavan disease. Statistically significant increases in brain enzyme activity levels have been achieved in this animal model, as well as decreases in the elevated substrate levels that mimic those found in Canavan disease patients. These results demonstrate that the modified enzyme is gaining access to the brain and functions to correct this metabolic defect. The stage is now set for a long term study to optimize this enzyme replacement approach for the development of a treatment protocol.

Original languageEnglish (US)
Pages (from-to)176-180
Number of pages5
JournalMolecular Genetics and Metabolism
Volume102
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Canavan Disease
Enzyme Replacement Therapy
Enzymes
Clinical Protocols
Therapeutics
Brain
Enzyme activity
aspartoacylase
Nervous System Diseases
Blood-Brain Barrier
Animals
Animal Models
Defects

Keywords

  • Animal model
  • Aspartoacylase
  • Canavan disease
  • Enzyme replacement therapy
  • PEGylation

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease. / Zano, Stephen; Malik, Radhika; Szucs, Sylvia; Matalon, Reuben; Viola, Ronald E.

In: Molecular Genetics and Metabolism, Vol. 102, No. 2, 02.2011, p. 176-180.

Research output: Contribution to journalArticle

Zano, Stephen ; Malik, Radhika ; Szucs, Sylvia ; Matalon, Reuben ; Viola, Ronald E. / Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease. In: Molecular Genetics and Metabolism. 2011 ; Vol. 102, No. 2. pp. 176-180.
@article{071df2a895894e448c9817143f82dff6,
title = "Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease",
abstract = "Canavan disease is a fatal neurological disease without any effective treatments to slow the relentless progress of this disorder. Enzyme replacement therapy has been used effectively to treat a number of metabolic disorders, but the presence of the blood-brain-barrier presents an additional challenge in the treatment of neurological disorders. Studies have begun with the aim of establishing a treatment protocol that can effectively replace the defective enzyme in Canavan disease patients. The human enzyme, aspartoacylase, has been cloned, expressed and purified, and the surface lysyl groups modified through PEGylation. Fully active modified enzymes were administered to mice that are defective in this enzyme and that show many of the symptoms of Canavan disease. Statistically significant increases in brain enzyme activity levels have been achieved in this animal model, as well as decreases in the elevated substrate levels that mimic those found in Canavan disease patients. These results demonstrate that the modified enzyme is gaining access to the brain and functions to correct this metabolic defect. The stage is now set for a long term study to optimize this enzyme replacement approach for the development of a treatment protocol.",
keywords = "Animal model, Aspartoacylase, Canavan disease, Enzyme replacement therapy, PEGylation",
author = "Stephen Zano and Radhika Malik and Sylvia Szucs and Reuben Matalon and Viola, {Ronald E.}",
year = "2011",
month = "2",
doi = "10.1016/j.ymgme.2010.10.012",
language = "English (US)",
volume = "102",
pages = "176--180",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease

AU - Zano, Stephen

AU - Malik, Radhika

AU - Szucs, Sylvia

AU - Matalon, Reuben

AU - Viola, Ronald E.

PY - 2011/2

Y1 - 2011/2

N2 - Canavan disease is a fatal neurological disease without any effective treatments to slow the relentless progress of this disorder. Enzyme replacement therapy has been used effectively to treat a number of metabolic disorders, but the presence of the blood-brain-barrier presents an additional challenge in the treatment of neurological disorders. Studies have begun with the aim of establishing a treatment protocol that can effectively replace the defective enzyme in Canavan disease patients. The human enzyme, aspartoacylase, has been cloned, expressed and purified, and the surface lysyl groups modified through PEGylation. Fully active modified enzymes were administered to mice that are defective in this enzyme and that show many of the symptoms of Canavan disease. Statistically significant increases in brain enzyme activity levels have been achieved in this animal model, as well as decreases in the elevated substrate levels that mimic those found in Canavan disease patients. These results demonstrate that the modified enzyme is gaining access to the brain and functions to correct this metabolic defect. The stage is now set for a long term study to optimize this enzyme replacement approach for the development of a treatment protocol.

AB - Canavan disease is a fatal neurological disease without any effective treatments to slow the relentless progress of this disorder. Enzyme replacement therapy has been used effectively to treat a number of metabolic disorders, but the presence of the blood-brain-barrier presents an additional challenge in the treatment of neurological disorders. Studies have begun with the aim of establishing a treatment protocol that can effectively replace the defective enzyme in Canavan disease patients. The human enzyme, aspartoacylase, has been cloned, expressed and purified, and the surface lysyl groups modified through PEGylation. Fully active modified enzymes were administered to mice that are defective in this enzyme and that show many of the symptoms of Canavan disease. Statistically significant increases in brain enzyme activity levels have been achieved in this animal model, as well as decreases in the elevated substrate levels that mimic those found in Canavan disease patients. These results demonstrate that the modified enzyme is gaining access to the brain and functions to correct this metabolic defect. The stage is now set for a long term study to optimize this enzyme replacement approach for the development of a treatment protocol.

KW - Animal model

KW - Aspartoacylase

KW - Canavan disease

KW - Enzyme replacement therapy

KW - PEGylation

UR - http://www.scopus.com/inward/record.url?scp=78651419742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651419742&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2010.10.012

DO - 10.1016/j.ymgme.2010.10.012

M3 - Article

C2 - 21095151

AN - SCOPUS:78651419742

VL - 102

SP - 176

EP - 180

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

ER -